JP2024537139A - ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法 - Google Patents

ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法 Download PDF

Info

Publication number
JP2024537139A
JP2024537139A JP2024520707A JP2024520707A JP2024537139A JP 2024537139 A JP2024537139 A JP 2024537139A JP 2024520707 A JP2024520707 A JP 2024520707A JP 2024520707 A JP2024520707 A JP 2024520707A JP 2024537139 A JP2024537139 A JP 2024537139A
Authority
JP
Japan
Prior art keywords
kras
inhibitor
pharma
salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537139A5 (https=
Inventor
ハリン，ジル
クリステンセン，ジェームズ・ゲイル
ボウカット，ビッキー
オルソン，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2024537139A publication Critical patent/JP2024537139A/ja
Publication of JP2024537139A5 publication Critical patent/JP2024537139A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024520707A 2021-10-05 2022-10-04 ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法 Pending JP2024537139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252384P 2021-10-05 2021-10-05
US63/252,384 2021-10-05
PCT/US2022/045619 WO2023059594A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024537139A true JP2024537139A (ja) 2024-10-10
JP2024537139A5 JP2024537139A5 (https=) 2025-09-30

Family

ID=85803703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520707A Pending JP2024537139A (ja) 2021-10-05 2022-10-04 ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法

Country Status (10)

Country Link
US (1) US20240408098A1 (https=)
EP (1) EP4412716A4 (https=)
JP (1) JP2024537139A (https=)
KR (1) KR20240073112A (https=)
CN (1) CN118338904A (https=)
AU (1) AU2022359282A1 (https=)
CA (1) CA3233566A1 (https=)
IL (1) IL311834A (https=)
MX (1) MX2024004213A (https=)
WO (1) WO2023059594A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025080956A1 (en) * 2023-10-12 2025-04-17 Mirati Therapeutics, Inc. Mrtx1133 pharmaceutical compositions
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2014142660A1 (en) 2013-03-12 2014-09-18 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer and kras-mutant colon cancer
AU2019355574A1 (en) 2018-10-05 2021-05-06 Sloan-Kettering Institute For Cancer Research PI3K inhibitors and uses thereof
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
US20240139193A1 (en) * 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4225383A4 (en) * 2020-10-08 2024-12-11 Kumquat Biosciences Inc. MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES

Also Published As

Publication number Publication date
KR20240073112A (ko) 2024-05-24
CA3233566A1 (en) 2023-04-13
AU2022359282A1 (en) 2024-04-11
US20240408098A1 (en) 2024-12-12
IL311834A (en) 2024-05-01
EP4412716A1 (en) 2024-08-14
WO2023059594A1 (en) 2023-04-13
EP4412716A4 (en) 2025-08-13
MX2024004213A (es) 2024-07-29
CN118338904A (zh) 2024-07-12

Similar Documents

Publication Publication Date Title
JP2024537139A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法
JP7546549B2 (ja) 組み合わせ療法
JP2025000630A (ja) 組み合わせ療法
JP2024540839A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法
JP2022500388A (ja) 組み合わせ療法
JP2024537137A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法
JP2024521788A (ja) 併用療法
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
CN119031916A (zh) 包含sos1抑制剂和egfr抑制剂的组合疗法
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
US20250186453A1 (en) Combination therapies comprising a sos1 inhibitor and a mek inhibitor
HK40108895A (zh) Kras g12d抑制剂与pi3ka抑制剂的组合及相关治疗方法
TW202428280A (zh) 組合療法
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
HK40101229A (zh) 组合疗法
CN117615762A (zh) 组合疗法
HK40108579A (zh) Kras g12d抑制剂与伊立替康的组合及相关治疗方法
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
HK40109895A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919